Patents by Inventor John W. Commissiong

John W. Commissiong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF ENHANCING DOPAMINERGIC NEURONAL CELL GROWTH OR SURVIVAL WITH MANF
    Publication number: 20190060402
    Abstract: Methods and compositions for enhancing dopaminergic neuronal cell growth or survival by administration of mesencephalic astrocyte-derived neurotrophic factor (MANF) to specific brain regions.
    Type: Application
    Filed: February 6, 2018
    Publication date: February 28, 2019
    Inventor: John W. COMMISSIONG
  • DOPAMINERGIC NEURONAL SURVIVAL-PROMOTING FACTORS AND USES THEREOF
    Publication number: 20170298110
    Abstract: In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a pharmaceutical composition that includes MANF and a pharmaceutically-acceptable excipient, methods for treatment of a neurodegenerative disease, methods for improving dopaminergic neuronal survival during or following cell transplantation, methods for production of neurons for transplantation, and methods for identifying compounds that modulate or mimic MANF's biological activity.
    Type: Application
    Filed: February 27, 2017
    Publication date: October 19, 2017
    Inventors: John W. COMMISSIONG, Andrei A. RAIBEKAS
  • Dopaminergic Neuronal Survival-Promoting Factors and Uses Thereof
    Publication number: 20160152673
    Abstract: In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a pharmaceutical composition that includes MANF and a pharmaceutically-acceptable excipient, methods for treatment of a neurodegenerative disease, methods for improving dopaminergic neuronal survival during or following cell transplantation, methods for production of neurons for transplantation, and methods for identifying compounds that modulate or mimic MANF's biological activity.
    Type: Application
    Filed: June 30, 2015
    Publication date: June 2, 2016
    Inventors: John W. Commissiong, Andrei A. Raibekas
  • Dopaminergic neuronal survival-promoting factors and uses thereof
    Patent number: 9115208
    Abstract: In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a pharmaceutical composition that includes MANF and a pharmaceutically-acceptable excipient, methods for treatment of a neurodegenerative disease, methods for improving dopaminergic neuronal survival during or following cell transplantation, methods for production of neurons for transplantation, and methods for identifying compounds that modulate or mimic MANF's biological activity.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: August 25, 2015
    Assignee: AMARANTUS THERAPEUTICS, INC.
    Inventors: John W. Commissiong, Andrei A. Raibekas
  • DOPAMINERGIC NEURONAL SURVIVAL-PROMOTING FACTORS AND USES THEREOF
    Publication number: 20130078220
    Abstract: In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a pharmaceutical composition that includes MANF and a pharmaceutically-acceptable excipient, methods for treatment of a neurodegenerative disease, methods for improving dopaminergic neuronal survival during or following cell transplantation, methods for production of neurons for transplantation, and methods for identifying compounds that modulate or mimic MANF's biological activity.
    Type: Application
    Filed: November 28, 2011
    Publication date: March 28, 2013
    Inventors: JOHN W. COMMISSIONG, ANDREI A. RAIBEKAS
  • Dopaminergic neuronal survival-promoting factors and uses thereof
    Patent number: 8084425
    Abstract: In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a pharmaceutical composition that includes MANF and a pharmaceutically-acceptable excipient, methods for treatment of a neurodegenerative disease, methods for improving dopaminergic neuronal survival during or following cell transplantation, methods for production of neurons for transplantation, and methods for identifying compounds that modulate or mimic MANF's biological activity.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: December 27, 2011
    Inventors: John W. Commissiong, Andrei A. Raibekas
  • NEURODEGENERATIVE DISORDERS
    Publication number: 20110212055
    Abstract: Methods and compositions for treating neuropathies.
    Type: Application
    Filed: March 25, 2009
    Publication date: September 1, 2011
    Inventor: John W. Commissiong
  • DOPAMINERGIC NEURONAL SURVIVAL-PROMOTING FACTORS AND USES THEREOF
    Publication number: 20100119491
    Abstract: In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a pharmaceutical composition that includes MANF and a pharmaceutically-acceptable excipient, methods for treatment of a neurodegenerative disease, methods for improving dopaminergic neuronal survival during or following cell transplantation, methods for production of neurons for transplantation, and methods for identifying compounds that modulate or mimic MANF's biological activity.
    Type: Application
    Filed: August 4, 2009
    Publication date: May 13, 2010
    Inventors: John W. Commissiong, Andrei A. Raibekas
  • Dopaminergic neuronal survival-promoting factors and uses thereof
    Publication number: 20020182198
    Abstract: In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a pharmaceutical composition that includes MANF and a pharmaceutically-acceptable excipient, methods for treatment of a neurodegenerative disease, methods for improving dopaminergic neuronal survival during or following cell transplantation, methods for production of neurons for transplantation, and methods for identifying compounds that modulate or mimic MANF's biological activity.
    Type: Application
    Filed: March 20, 2002
    Publication date: December 5, 2002
    Inventors: John W. Commissiong, Andrei A. Raibekas